Sistema de Salut de Catalunya
[Izquierdo-Domínguez A] Servei d’Al·lergologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain. Unidad Alergo-Rino, Centro Médico Teknon, Barcelona, Spain. Department of Allergy, Clínica Diagonal, Barcelona, Spain. [Rojas-Lechuga MJ] Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain. Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain. CIBER of Respiratory Diseases, Madrid, Spain. [Alobid I] Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain. Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain. CIBER of Respiratory Diseases, Madrid, Spain. Unidad Alergo-Rino, Centro Médico Teknon, Barcelona, Spain
Consorci Sanitari de Terrassa
2023-09-29T12:08:57Z
2023-09-29T12:08:57Z
2021-02-09
Coronavirus infections; Rhinitis, Allergic; Drug hypersensitivity
Infecciones por coronavirus; Rinitis alérgica; Hipersensibilidad medicamentosa
Infeccions per coronavirus; Rinitis al·lèrgica; Hipersensibilitat medicamentosa
Purpose of review: The coronavirus disease 2019 (COVID-19) has challenged healthcare system capacities and safety for health care workers, reshaping doctor-patient interaction favoring e-Health or telemedicine. The pandemic situation may make difficult to prioritize patients with allergies diseases (AD), face-to-face evaluation, and moreover concern about the possible COVID-19 diagnosis, since COVID-19 shared many symptoms in common with AD. Being COVID-19 a novel disease, everyone is susceptible; there are some advances on vaccine and specific treatment. We evaluate existing literature on allergic diseases (AD): allergic rhinitis, asthma, food allergy, drug allergy, and skin allergy, and potential underlying mechanisms for any interrelationship between AD and COVID-19. Recent findings: There is inconclusive and controversial evidence of the association between AD and the risk of adverse clinical outcomes of COVID-19. AD patients should minimize hospital and face-to-face visits, and those who have used biologics and allergen immunotherapy should continue the treatment. It is essential to wear personal protective equipment for the protection of health care workers. Social distancing, rational use of facemasks, eye protection, and hand disinfection for health care workers and patients deserve further attention and promotion. Teleconsultation during COVID-19 times for AD patients is very encouraging and telemedicine platform can provide a reliable service in patient care.
Article
Published version
English
Rinitis; Al·lèrgia alimentària; COVID-19 (Malaltia); DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; DISEASES::Respiratory Tract Diseases::Nose Diseases::Rhinitis::Rhinitis, Allergic; DISEASES::Immune System Diseases::Hypersensitivity::Drug Hypersensitivity; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; ENFERMEDADES::enfermedades respiratorias::enfermedades nasales::rinitis::rinitis alérgica; ENFERMEDADES::enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad medicamentosa
Springer
Current Allergy and Asthma Reports;21(2)
https://doi.org/10.1007/s11882-021-00989-x
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
